Prognostic value of the mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX
Background: KRAS , TP53 , CDKN2A , and SMAD4 have been the main driver mutations in pancreatic ductal adenocarcinoma (PDAC). Studies on the clinical significance and treatment response to 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) regimen in terms of the presence of these m...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-10-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241290482 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|